Invizius announces successful Series A financing to develop anti-inflammatory treatment for haemodialysis

  • £5.3 million financing to complete First-in-Man safety study
  • Led by Mercia, Downing Ventures, Old College Capital, Scottish Enterprise and Solvay Ventures; welcomes new investors Calculus Capital and Dr Jonathan Milner

Invizius, a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has closed Series A financing of £5.3 million. The financing was led by existing investors Mercia, Downing Ventures, Old College Capital, Scottish Enterprise, Solvay Ventures and new investors Calculus Capital and experienced life science entrepreneur and investor, Dr Jonathan Milner. Although already over-subscribed, the company’s Series A remains open to other investors until June 2021.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH